publication date: Oct. 2, 2020

NCI Trials

NCI Trials for Oct. 2020

The National Cancer Institute approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.


Phase I – 10410

A Phase 1 Study of IPdR in Combination with Capecitabine and Radiotherapy in Rectal Cancer

University Health Network Princess Margaret Cancer Center LAO

Kinsella, Timothy James

(401) 444-6203


Phase II – 10398

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma

National Cancer Institute LAO

Chen, A P

(240) 781-3320


Phase II – S2000

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases


Eroglu, Zeynep

(813) 745-8581


Phase II/III – EA2197

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

ECOG-ACRIN Cancer Research Group

Maithel, Shishir Kumar

(404) 617-7936


Phase III – EA2176

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-NaÔve Metastatic Anal Cancer Patients

ECOG-ACRIN Cancer Research Group

Eng, Cathy



Phase III – EA5182

Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

ECOG-ACRIN Cancer Research Group

Yu, Helena A.

(646) 888-4274


Phase III – NRG-HN007

An Open-Label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

NRG Oncology

Ma, Brigette Buig-Yue

852- 35052118


Phase Other – 10323

Cancer Moonshot Biobank Research Protocol

Division of Cancer Treatment and Diagnosis

Moore, Helen M.

(240) 276-5713

Copyright (c) 2020 The Cancer Letter Inc.